The Data Highlights section showcases recently published datasets on COVID-19 and SARS-CoV-2 by researchers affiliated with a Swedish research institute. The goal is to highlight openly shared data that can potentially be used by many other researchers to make further discoveries. If you have published or are about to publish data that you think should be highlighted in this section, you are welcome to send us a suggestion.
One year ago today, on June 3rd 2020, the Swedish COVID-19 Data Portal was launched and became the first national node of the European data sharing platform for COVID-19 research efforts. Here, we look back at the highlights over the last year.
Saccon and colleagues studied changes in protein abundance caused by SARS-CoV-2 virus in susceptible cell lines using quantitative proteomics. All proteomics were made data openly available in different repositories.
Recent study examined a large number of inflammatory, immune response, cardiovascular, and neurological markers in the blood of patients variously impacted by COVID-19. Data and analysis code were shared in public repositories.
COVID Symptom Study Sweden collects data through a smartphone app to investigate prevalence, risk factors, and symptoms associated with COVID-19. To date, over 200.000 volunteers have enrolled in the study.
The Swedish COVID-19 Data Portal is launching a section with wastewater epidemiology data. Weekly data from Uppsala, Stockholm, Umeå, and Örebro is presented in graphs and available for download.
A new study largely relying on existing data re-use identified circulating proteins influencing COVID-19 susceptibility and severity. Based on these results, work on repurposing relevant existing drugs work can now be launched.
In collaboration with Biobank Sweden, today we are launching a new section of the portal: the Swedish COVID-19 Sample Collection Database. The database allows to search for available biobank sample collections.
A recently published clinical study investigating bevacizumab, a humanized anti-VEGF monoclonal antibody, offers promising results in fighting severe COVID-19. Treatment progress data and analysis code were shared publicly.
A recently published study characterizes the mechanisms by which nanobodies neutralize or prevent of infection in molecular detail. Crystallographic coordinates, cryo-EM density maps, and atomic coordinates were deposited to public databases.
Mechanism of entry used by human species D adenoviruses proving important for COVID-19 vaccine development
New study identifies a noncanonical entry mechanism used by human adenoviruses, important for development of adenovirus-based vaccine vectors. The reported X-ray structural data was made available through the Protein Data Bank.
Newly discovered antiviral compounds showed broad-range antiviral activity against pathogenic RNA viruses such as SARS-CoV-2. The authors share data freely in open repositories.
Multiple autoantibodies and specific cytokines could be involved in the pathogenesis of MIS-C associated with COVID-19. Data and code made available in open repositories.
Leo Hanke and colleagues identified a SARS-CoV-2 RBD-specific single domain antibody fragment, Ty1, that potently neutralizes the virus. Ty1 should now be further investigated as a candidate for antiviral therapy.
Recently published study demonstrates that it is possible to select highly specific binders with neutralizing activity against SARS-CoV-2 from a synthetic nanobody library in a short timeframe.
Tiphaine Parrot and colleagues studied changes in conventional and unconventional T cell subsets in patients with various disease severity using flow cytometry. The results were published along with the data.
A study by Rogstam and colleagues published along with the crystal structure of SARS CoV-2 non-structural protein 10 in the Protein Data Bank provides a starting point for structure-guided drug discovery and design.
Patrick Bryant and Arne Elofsson shared code and instructions for modelling COVID-19 development using MCMC simulations based on mobile phone mobility data from Google mobility reports.
First study using data collected as part of the large-scale serology testing at SciLifeLab published
This study used only a fraction of the large volume of serology data continuously collected by the ScilifeLab Autoimmunity and Serology profiling facility.
Study by Hugo Zeberg and Svante Pääbo fully based on openly available data published open access in Nature.
Study by Björn Reinius and co-workers published open access in Nature Communications along with source data and the computational code.
We are launching a page with statistics on the SARS-CoV-2 antibody tests carried out at the SciLifeLab Autoimmunity and Serology profiling facility.